First-Line Disease-Modifying Therapies in Paediatric Multiple Sclerosis: A Comprehensive Overview

ISSN： 0012-6667

Source： Drugs, Vol.72, Iss.9, 2012-06, pp. : 1195-1211

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Emerging disease modifying therapies for multiple sclerosis

By Waubant Emmanuelle

Expert Opinion on Emerging Drugs, Vol. 8, Iss. 1, 2003-05 ,pp. : 145-161

Informa Healthcare

Access to resources Recommend Favorite

Current and prospective disease-modifying therapies for amyotrophic lateral sclerosis

By Morren John A Galvez-Jimenez Nestor

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 3, 2012-03 ,pp. : 297-320

Informa Healthcare

Access to resources Recommend Favorite

Cost-Effectiveness Analyses of Natalizumab (Tysabri ® ) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK

By Gani Ray

PharmacoEconomics, Vol. 26, Iss. 7, 2008-01 ,pp. : 617-627

Adis International

Access to resources Recommend Favorite

Disease-Modifying Agents for Multiple Sclerosis: Recent Advances and Future Prospects

By Menge Til

Drugs, Vol. 68, Iss. 17, 2008-01 ,pp. : 2445-2468

Adis International

Access to resources Recommend Favorite

Oral Disease-Modifying Treatments for Multiple Sclerosis: The Story So Far

By Kieseier Bernd C.

CNS Drugs, Vol. 21, Iss. 6, 2007-01 ,pp. : 483-502

Adis International

Access to resources Recommend Favorite